CDC: Chronic Fatigue Syndrome Prevalence 1.3 Percent in 2021 to 2022

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 8, 2023 -- The prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in the United States in 2021 to 2022 was 1.3 percent, according to a December data brief published by the U.S. Centers for Disease Control and Prevention National Center for Health Statistics.

Anjel Vahratian, Ph.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the 2021 to 2022 National Health Interview Survey to describe the percentage of adults who had ME/CFS by selected demographic and geographic characteristics.

The researchers found that 1.3 percent of adults had ME/CFS in 2021 to 2022. There was an increase seen in the percentage of adults with ME/CFS with age through ages 60 to 69 years, followed by a decrease among those aged 70 years and older. The likelihood of having ME/CFS was higher for White non-Hispanic adults than Asian non-Hispanic and Hispanic adults (1.5 percent versus 0.7 and 0.8 percent, respectively). The likelihood of having ME/CFS was higher for adults with a family income less than 100 percent of the federal poverty level, followed by those at 100 to 199 percent and those at or above 200 percent (2.0, 1.7, and 1.1 percent, respectively). With increasing rurality of place of residence, the percentage of adults who had ME/CFS increased.

"As the prevalence estimates in this report are based on a doctor's diagnosis, adults who are undiagnosed are not included in this analysis," the authors write. "True prevalence estimates may be higher, as previous studies suggest that many people with ME/CFS are undiagnosed."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-09 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords